Results 51 to 60 of about 2,172,183 (156)
Contact Dermatitis, Volume 95, Issue 4, Page 349-357, October 2026.ABSTRACT Drug hypersensitivity reactions (DHRs) are common in children and are diagnostically challenging, with cutaneous manifestations being the most common presentation. Patch testing (PT) is a well‐established tool for investigating delayed T‐cell‐mediated reactions and is widely used in patients with contact dermatitis.
Gabriele Simonetti +7 more
wiley +1 more source
Cancer Medicine, Volume 15, Issue 9, September 2026.ABSTRACT Background T‐cell–engaging bispecific antibodies are increasingly utilised in haematological malignancies and are beginning to be adopted in solid‐tumour treatment protocols. Cytokine release syndrome and neurotoxicity are well recognised, but target‐specific dermatological adverse event reporting patterns remain poorly defined.
Saikat Mandal +2 more
wiley +1 more source
Contact Dermatitis, Volume 95, Issue 3, Page 237-275, September 2026.ABSTRACT The present guideline updates the initial ESCD patch testing guideline, summarizing all aspects of patch testing for the diagnosis of contact allergy in patients suspected of suffering, or having been suffering, from allergic contact dermatitis or other delayed‐type hypersensitivity skin and mucosal conditions. Sections with brief descriptions
Wolfgang Uter +23 more
wiley +1 more source
Ciprofloxacin induced acute generallised exanthematous pustulosis
, 2017 Acute generalized exanthematous pustulosis (AGEP) is an uncommon and self-limiting skin rash commonly caused by drugs and is characterized by the acute onset of fever, pustulosis, and neutrophilia from 4 to 10 days after the drug intake.
Bonamonte D. +7 more
core +2 more sources
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Toxic epidermal necrolysis (TEN) is a rare but life‐threatening mucocutaneous adverse drug reaction characterized by widespread epidermal necrosis and detachment with significant mucosal involvement. We report a case of near total (80%–90%) body surface area TEN in a previously healthy 30‐year‐old man that developed approximately 5 days after ...
Amanuel D. Wakoya +6 more
wiley +1 more source
Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.ABSTRACT Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs.
Ana Maria Copaescu +13 more
wiley +1 more source
Epilepsia Open, Volume 11, Issue 4, Page 1255-1262, August 2026.Abstract Objective To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation. Methods We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective ...
Marina Feldman +4 more
wiley +1 more source
Clinical Case Reports, 2023 Key Clinical Message Hydroxychloroquine (HCQ) has been reported to cause pustular drug eruptions such as acute generalized exanthematous pustulosis (AGEP) and putular psoriasis (PP). Clinical differentitation of these entities is often difficult.
Jeffrey Chen +4 more
doaj +1 more source
Health Science Reports, Volume 9, Issue 8, August 2026.ABSTRACT Background and Aims The HLA‐B*15:02 allele is related to a high risk of severe cutaneous adverse drug reactions (SCARs) in patients taking certain antiepileptic drugs. However, its prevalence in the Asian population and the number of drugs linked to SCARs due to the carriage of this variant are relatively underexplored.
Mohitosh Biswas +3 more
wiley +1 more source